您的位置: 首页 > 2025年5月 第56卷 第5期 > 文字全文
2023年7月 第38卷 第7期11
目录

CT、MRI影像学表现对原发性肝细胞癌微血管侵犯的诊断价值

Diagnostic value of CT and MRI imaging manifestations for microvascular invasion in primary hepatocellular carcinoma

来源期刊: 广州医药 | 681-688 发布时间:2025-06-17 收稿时间:2025/11/13 18:53:51 阅读量:33
作者:
关键词:
肝细胞微血管侵犯体层摄影术X线计算机磁共振成像
carcinomahepatocytesmicrovascular invasiontomographyX-ray computermagnetic resonance imaging
DOI:
10.20223/j.cnki.1000-8535.2025.05.016
收稿时间:
2024-10-18 
修订日期:
 
接收日期:
 
引用总数:
0  
目的 探讨CT、MRI影像学表现对原发性肝细胞癌(HCC)微血管侵犯(MVI)的诊断价值。方法 选取2018年1月—2024年7月江门市第二人民医院(江门市中心医院蓬江分院)和江门市中心医院120例(共158个病灶)HCC患者,均行上腹部CT、MRI平扫+增强及弥散加权成像(DWI)检查;以术后病理结果为金标准。比较CT、MRI平扫+增强及DWI对HCC MVI诊断效能;分析HCC MVI诊断中CT、MRI平扫+增强及DWI检查与术后病理确诊结果之间的一致性;比较HCC MVI与无HCC MVI患者影像学表现及表观扩散系数(ADC)值。结果 DWI检查对HCC MVI的诊断效能(灵敏度、特异度、准确度、阳性预测值、阴性预测值)均显著性高于CT、MRI平扫+增强(P<0.05);CT、MRI、DWI对原发性肝细胞癌患者微血管侵犯的诊断效能比较,差异均无统计学意义(P>0.05)。在HCC MVI诊断效能中,CT、MRI影像学表现与术后病理确诊结果之间为中度一致性;DWI与术后病理确诊结果之间为高度一致性。HCC MVI患者的强化方式在非边缘动脉期强化、强化包膜、晕状强化、结中结、门脉分支癌栓占比均显著性高于无HCC MVI患者(P<0.05)。在不同b值(400、800、1 000、1 500 s/mm2)下,HCC MVI患者的ADC值均显著性高于无HCC MVI患者(P<0.05)。结论 CT、MRI平扫+增强及DWI对HCC MVI均具有较好的诊断效能,而MRI诊断结果与病理诊断一致性更佳,尤其DWI图中ADC值可更加精准地判断HCC的患者是否发生微血管侵犯,有助于指导临床医生建立“个体化”精准诊疗策略。
Objective To explore the diagnostic value of CT and MRI imaging manifestations for microvascular invasion(MVI)in primary hepatocellular carcinoma(HCC).Methods A total of 120 patients(158 lesions in total)with HCC in the Second People’s Hospital of Jiangmen(Pengjiang Branch of Jiangmen Central Hospital)and Jiangmen Central Hospital were selected from January 2018 to July 2024,all underwent CT and MRI plain + enhanced and diffusion-weighted imaging(DWI)of the upper abdomen;postoperative pathology Results was used as the diagnostic gold standard.The diagnostic efficacy of CT,MRI plain + enhanced and DWI for HCC MVI was compared.The concordance among CT,MRI plain + enhanced and DWI examinations with postoperative pathological diagnostic findings in the diagnosis of HCC MVI.Imaging manifestations and apparent diffusion coefficient(ADC)values in patients with and without HCC MVI were compared.Results Diagnostic effectiveness of DWI examination for HCC MVI(sensitivity,specificity,accuracy,positive predictive value,negative predictive value)were all significantly higher than those of CT and MRI plain + enhanced(P<0.05);none of the differences were statistically significant(P>0.05)in the comparison of diagnostic effectiveness of CT,MRI,and DWI for the diagnosis of MVI in patients with primary HCC.In HCC MVI diagnostic effectiveness,moderate concordance was found among CT,MRI imaging phenotypes and postoperative pathology Results;high concordance was found between DWI and postoperative pathology Results.In HCC MVI patients,the proportion of non-marginal arterial reinforcement,enhanced envelope,halo reinforcement,nodal in nodal and portal branch cancer thrombi was significantly higher than that in patients without HCC MVI(P<0.05).At different b-values(400,800,1 000,1 500 s/mm2),ADC values were all significantly higher in patients with HCC MVI than in patients without HCC MVI(P<0.05).Conclusions CT,MRI plain + enhanced and DWI have good diagnostic effectiveness for HCC MVI,while MRI diagnostic Results are in better concordance with pathologic diagnosis.In particular,ADC values in DWI maps can more accurately determine whether MVI occurs in patients with HCC,which helps to guide clinicians to establish“individualized”and precise diagnosis and treatment strategies.
1、 王晶,张泉,谷鹏,等.经导管动脉化疗栓塞治疗前MR-DWI的不同b值下ADC值对肝细胞癌患者肿瘤进展的评估比较[J].中国普外基础与临床杂志,2020,27(10):1236-1240. 王晶,张泉,谷鹏,等.经导管动脉化疗栓塞治疗前MR-DWI的不同b值下ADC值对肝细胞癌患者肿瘤进展的评估比较[J].中国普外基础与临床杂志,2020,27(10):1236-1240.
2、 RENZULLI M,BROCCHI S,CUCCHETTI A,et al.Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma?[J].Radiology,2016,279(2):432-442. RENZULLI M,BROCCHI S,CUCCHETTI A,et al.Can current preoperative imaging be used to detect microvascular invasion of hepatocellular carcinoma?[J].Radiology,2016,279(2):432-442.
3、 鲁梦恬,张学琴,张涛,等.MRI特征评分模型预测增殖型肝细胞癌[J].中国医学影像技术,2024,40(6):874-879. 鲁梦恬,张学琴,张涛,等.MRI特征评分模型预测增殖型肝细胞癌[J].中国医学影像技术,2024,40(6):874-879.
4、 樊伟. 原发性肝细胞癌CT及MRI影像学表现特征及诊断价值分析[J].实用中西医结合临床,2021,21(6):117-118,122. 樊伟. 原发性肝细胞癌CT及MRI影像学表现特征及诊断价值分析[J].实用中西医结合临床,2021,21(6):117-118,122.
5、 BRANCATO V,GARBINO N,SALVATORE M,et al.MRI-based radiomic features help identify lesions and predict histopathological grade of hepatocellular carcinoma[J].Diagnostics(Basel),2022,12(5):1085. BRANCATO V,GARBINO N,SALVATORE M,et al.MRI-based radiomic features help identify lesions and predict histopathological grade of hepatocellular carcinoma[J].Diagnostics(Basel),2022,12(5):1085.
6、 CHEN W,ZHANG T,XU L,et al.Radiomics analysis of contrast-enhanced CT for hepatocellular carcinoma grading[J].Front Oncol,2021(11):660509. CHEN W,ZHANG T,XU L,et al.Radiomics analysis of contrast-enhanced CT for hepatocellular carcinoma grading[J].Front Oncol,2021(11):660509.
7、 于世民. CT、MRI及DWI在肝细胞癌微血管浸润诊断中的应用价值[J].临床医学研究与实践,2022,7(8):113-116. 于世民. CT、MRI及DWI在肝细胞癌微血管浸润诊断中的应用价值[J].临床医学研究与实践,2022,7(8):113-116.
8、 曹素园,刘强.基于MRI术前诊断肝细胞癌MVI的研究进展[J].医学影像学杂志,2022,32(4):679-681. 曹素园,刘强.基于MRI术前诊断肝细胞癌MVI的研究进展[J].医学影像学杂志,2022,32(4):679-681.
9、 TIETZ E,TRUHN D,MULLER-FRANZES G,et al.A radiomics approach to predict the emergence of new hepatocellular carcinoma in computed tomography for high-risk patients with liver cirrhosis[J].Diagnostics(Basel),2021,11(9):1650. TIETZ E,TRUHN D,MULLER-FRANZES G,et al.A radiomics approach to predict the emergence of new hepatocellular carcinoma in computed tomography for high-risk patients with liver cirrhosis[J].Diagnostics(Basel),2021,11(9):1650.
10、 HUANG K,DONG Z,CAI H,et al.Imaging biomarkers for well and moderate hepatocellular carcinoma:Preoperative magnetic resonance image and histopathological correlation[J].BMC Cancer,2019,19(1):364. HUANG K,DONG Z,CAI H,et al.Imaging biomarkers for well and moderate hepatocellular carcinoma:Preoperative magnetic resonance image and histopathological correlation[J].BMC Cancer,2019,19(1):364.
11、 WANG Y,TIAN X,TIAN J,et al.Is gadoxetic acid disodium(Gd-EOB-DTPA)-enhanced magnetic resonance imaging an accurate diagnostic method for hepatocellular carcinoma? A systematic review with meta-analysis[J].Curr Med Imaging,2022,18(6):633-647. WANG Y,TIAN X,TIAN J,et al.Is gadoxetic acid disodium(Gd-EOB-DTPA)-enhanced magnetic resonance imaging an accurate diagnostic method for hepatocellular carcinoma? A systematic review with meta-analysis[J].Curr Med Imaging,2022,18(6):633-647.
12、 陈祝愿,秦传波,王栋,等.基于频率引导和一致性校正的半监督腹部CT嗜铬细胞瘤分割[J/OL].机电工程技术,1-8[2025-05-22].http://kns.cnki.net/kcms/detail/44.1522.TH.20250313.1626.006.html. 陈祝愿,秦传波,王栋,等.基于频率引导和一致性校正的半监督腹部CT嗜铬细胞瘤分割[J/OL].机电工程技术,1-8[2025-05-22].http://kns.cnki.net/kcms/detail/44.1522.TH.20250313.1626.006.html.
13、 LI J,YANG F,LI J,et al.Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion[J].World J Gastrointest Surg,2023,15(1):19-31. LI J,YANG F,LI J,et al.Postoperative adjuvant therapy for hepatocellular carcinoma with microvascular invasion[J].World J Gastrointest Surg,2023,15(1):19-31.
14、 MULE S,GALLETTO PREGLIASCO A,TENENHAUS A,et al.Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma[J].Radiology,2020,295(3):562-571. MULE S,GALLETTO PREGLIASCO A,TENENHAUS A,et al.Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma[J].Radiology,2020,295(3):562-571.
15、 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中华肝脏病杂志,2022,30(4):367-388. 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗指南(2022年版)[J].中华肝脏病杂志,2022,30(4):367-388.
16、 LOY L M,LOW H M,CHOI J Y,et al.Variant hepatocellular carcinoma subtypes according to the 2019 WHO classification:An imaging-focused review[J].AJR Am J Roentgenol,2022,219(2):212-223. LOY L M,LOW H M,CHOI J Y,et al.Variant hepatocellular carcinoma subtypes according to the 2019 WHO classification:An imaging-focused review[J].AJR Am J Roentgenol,2022,219(2):212-223.
17、 IVANICS T,RAJENDRAN L,ABREU P A,et al.Long-term outcomes of ablation,liver resection,and liver transplant as first-line treatment for solitary HCC of 3 cm or less using an intention-to-treat analysis:A retrospective cohort study[J].Ann Med Surg(Lond),2022(77):103645. IVANICS T,RAJENDRAN L,ABREU P A,et al.Long-term outcomes of ablation,liver resection,and liver transplant as first-line treatment for solitary HCC of 3 cm or less using an intention-to-treat analysis:A retrospective cohort study[J].Ann Med Surg(Lond),2022(77):103645.
18、 LAMBIN P,LEIJENAAR R T H,DEIST T M,et al.Radiomics:The bridge between medical imaging and personalized medicine[J].Nat Rev Clin Oncol,2017,14(12):749-762. LAMBIN P,LEIJENAAR R T H,DEIST T M,et al.Radiomics:The bridge between medical imaging and personalized medicine[J].Nat Rev Clin Oncol,2017,14(12):749-762.
19、 van der POL C B,MCINNES M D F,SALAMEH J P,et al.CT/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma:Individual patient data meta-analysis[J].Radiology,2023,307(1):e239005. van der POL C B,MCINNES M D F,SALAMEH J P,et al.CT/MRI and CEUS LI-RADS major features association with hepatocellular carcinoma:Individual patient data meta-analysis[J].Radiology,2023,307(1):e239005.
20、 YANG J,LIANG H,HU K,et al.The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection:A systematic review and meta-analysis[J].Cancer Cell Int,2021,21(1):92. YANG J,LIANG H,HU K,et al.The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection:A systematic review and meta-analysis[J].Cancer Cell Int,2021,21(1):92.
21、 ZENG H M,CHEN W Q,ZHENG R S,et al.Changingcancer survival in China during 2003-15:A pooled analysis of 17 population-based cancer registries[J].Lancet Glob Health,2018,6(5):e555-e567. ZENG H M,CHEN W Q,ZHENG R S,et al.Changingcancer survival in China during 2003-15:A pooled analysis of 17 population-based cancer registries[J].Lancet Glob Health,2018,6(5):e555-e567.
22、 《原发性肝癌诊疗指南(2024 年版)》编写专家委员会.原发性肝癌诊疗指南(2024年版)[J].中国临床医学,2024,31(2):277-334. 《原发性肝癌诊疗指南(2024 年版)》编写专家委员会.原发性肝癌诊疗指南(2024年版)[J].中国临床医学,2024,31(2):277-334.
上一篇
下一篇
出版者信息








《广州医药》公众号
目录